Introduction
Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis (MF) are heterogeneous clonal stem cell disorders classified as Philadelphia negative chronic Myeloproliferative Neoplasms (MPNs), which are characterized by increased proliferation of erythroid, megakaryocytic and myeloid lineages (1) . Despite the recent discoveries of different genetic abnormalities involved in MPNs pathogenesis, JAK2V617F point mutation continues to occupy a unique position, since it is the most common lesion found in these diseases, occurring in the majority of PV (>95%) and in more than half of ET and MF. This mutation leads to a constitutive activation of the JAK-STAT signaling pathway (2, 3) and there is strong evidence that hematopoietic precursors bearing this mutation acquire a proliferative and survival advantage (4) (5) (6) .
The presence of the JAK2V617F is now included as a major criterion in the revised World Health Organization (WHO) diagnostic criteria for PV, whereas it is considered as a clonal marker for ET and MF (7) . Therefore, the molecular analysis of this mutation is mandatory in the diagnostic workup of MPNs as demonstrated by the wide variety of methodologies that have been described for its detection (8) (9) (10) (11) . Considering that the JAK2V617F allele burden at diagnosis is highly variable, the chosen method should be sensitive enough to detect low mutant allele levels, but also specific enough not to produce false positive results.
The JAK2V617F mutation can be present in a heterozygous state or can progress to homozygosity most frequently by a mitotic recombination event resulting in uniparental disomy.
Different studies suggested that in ET and PV a higher allele burden is associated to disease progression to MF (12) (13) (14) (15) , but in contrast, a low allele burden is related to an inferior overall and leukemia-free survival in MF (16) . Therefore, an estimation of the allele burden is clinically relevant and can be an important marker in monitoring the molecular response to the novel JAK2 inhibitors (17, 18) .
Several qualitative and quantitative molecular assays are currently available for the detection of the JAK2V617F mutation but each of them presents some important limitations, such as a low sensitivity and reproducibility and the requirement of labor-intensive procedures performed with expensive specialized equipment that may not always be readily available in clinical laboratories.
Allele-specific PCR is the most commonly used and allows the detection of an allele burden up to 1%, but it requires hands-on-time and care to achieve unambiguous results besides not being quantitative (3) . On the other hand, the amplification of exon 14 of JAK2, followed by an enzymatic digestion, can provide a reliable evaluation of the JAK2V617F allele burden (19) .
Pyrosequencing has the advantage of presenting sequence data "in real time", without an additional post-PCR procedure, and it is also semi-quantitative. However, the sensitivity is between 5% and 10% (20) . Finally, different quantitative assays are described in literature and some of them are commercially available, but yet, an accurate quantification of the JAK2V617F allele burden is still far (21) .
Here we present a novel non-PCR molecular method for the identification of the JAK2V617F mutation, based on the Loop mediated isothermal AMPlification (LAMP) principle (22) . This technique, called Allele Specific (AS)-LAMP, generates, within one hour, a large amount of amplified DNA, visible to the naked-eye that can also be monitored by Real-Time turbidimetry and not requiring gel separation. This simple, easy to perform and rapid assay selectively detects the JAK2V617F mutated DNA with high sensitivity. AGTGTGACTGGGCAGATCATCCACCTTC3'-TAMRA. The JAK2 copy number was calculated as previously described (23) . In keeping with similarly published results (24), a concordant JAK2 copy number was defined by both approaches: UKE-1, 2 copies; HEL, 12 copies;
SET-2, 5 copies; BJAB, 2 copies; K562, 2 copies (data not shown).
Patients
Genomic DNA was obtained from the peripheral blood of patients with PV (n= 36), ET (n= 58), MF (n= 4) and unclassified MPNs (n= 2). As control, DNA was also extracted from normal healthy donors (n= 73) and patients with Acute Lymphoblastic Leukemia (ALL, n= 2), Follicular non Hodgkin's Lymphoma (NHL, n= 2), B cell Chronic Lymphocytic Leukemia (B-CLL, n= 2).
All these subjects are routinely followed for clinical reasons at Ospedali Riuniti di Bergamo.
Sample preservation and genetic analysis required informed consent and approval by the Ethics Committee.
The AS-LAMP assay
The Loop mediated isothermal AMPlification (LAMP) of DNA (see Supplementary File 1)
was initially described by Notomi as an innovative tool to amplify DNA with high specificity, efficiency and rapidity under isothermal conditions (22) . The AS-LAMP reaction ( Figure 1 ) is based on the use of 4 primers specifically designed to recognize 6 distinct regions on the target gene: a pair of outer primers (F3 (GA231 5' GCATCTTTATTATGGCAGAGAG 3'); and B3
(GA232 5' TGCTCTGAGAAAGGCATTA 3')) and a pair of inner primers (FIP (GA233 5' GCTGCTTCAAAGAAAGACTAAGGAAATGGACAACAGTCAAACAAC 3') and BIP (GA234 Figure 1A ). The displaced product generates a "stem loop structure" which represents the starting structure for a classical LAMP reaction ( Figure 1B) . If the target gene is wild type, the specific PNA forms a stable duplex with the dumbbell structure, thus interfering with the annealing and extension of the mutant self-annealed primer ( Figure 1C ). In the case of few molecules not bound by the PNA, the amplification still does not proceed thanks to the auto-sequestration of the self-annealed primer, which cannot be extended by the polymerase since the intra-molecular hairpin structure melting temperature is higher than the primer-target hybridization one. If the target gene is mutated, the PNA does not anneal due to the single-base mismatch, while the self-annealed loop primer breaks its internal interaction to bind the target, being consequently extended ( Figure 1D ).
The assay is performed at 65°C constant temperature for 1 hour on the LA200 turbidimeter (Teramecs Co, Kyoto, Japan) instrument for real-time monitoring. The variation of absorbance in terms of arbitrary units (a.u.) can be analyzed to find the threshold time for each sample tested. The threshold time is the minute at which the sample absorbance, after baseline subtraction, reaches the a.u. value representing the threshold of 0.1 a.u., which coincides with the beginning of the exponential phase of the amplification process. Moreover, it guarantees reliable results and it is commonly adopted for LAMP applications used for the molecular diagnosis of infectious diseases Samples with an allele burdens below 10% can be directly defined as low positive (<10%).
Identification of JAK2V617F by PCR amplification
The Allele Specific Oligonucleotide (ASO) PCR for the JAK2V617F mutation was 
Results

Sensitivity and specificity of the AS-LAMP assay
The AS-LAMP method was initially tested on genomic DNA from three JAK2V617F mutant (UKE-1, SET-2 and HEL) and eight JAK2 wild type cell lines (HL60, TF1 proved consistently negative (data not shown).
To evaluate the ability of the AS-LAMP to detect low amounts of JAK2V617F mutated DNA, we optimized the assay on a JAK2V617F containing plasmid serially diluted into a JAK2 wild type plasmid. This allowed to reach a sensitivity of 0.05% (70 mutated copies/350000 total plasmid copies) (data not shown). Furthermore, we performed the assay using genomic DNA from the UKE-1 cell line serially diluted (100, 10, 1, 0.1, 0.05, 0.01 and 0%) into wild-type DNA from By the addition of an intercalating dye, AS-LAMP reaction was also monitored on a realtime instrument with a comparable rapid response and sensitivity (data not shown).
Evaluation of the JAK2V617F allele burden in clinical samples by AS-LAMP
To test the ability of the assay to define the JAK2V617F allele burden, experiments were planned using genomic DNA from UKE-1 serially diluted into wild type DNA from BJAB.
Samples containing a known amount of JAK2V617F mutated DNA (from 90% to 2%) were analyzed and compared to the standard curve prepared using three calibrators containing a JAK2V617F allele burden of 100%, 10% and 1%, respectively ( Figure 4A ). Samples with a T(t)min detected between 10% and 1% calibrators could be directly defined as low positive (allele burden <10%). For samples containing a JAK2V617F allele burden above 10%, the efficiency and speed of AS-LAMP do not allow an immediate definition of the tumor allele burden ( Figure 4A ). After a 1:5 12 dilution, samples with an allele burden below 50% showed a T(t)min higher than a 10% calibrator while samples with an allele burden between 90% and 60% showed a T(t)min comprised between that of 100% and 10% calibrators. As a matter of comparison, DNA from SET-2 cells showed an allele burden above 50% ( Figure 4B ). We then tested the AS-LAMP assay on DNA obtained from freshly isolated peripheral blood leukocytes from 19 PV patients for whom the JAK2V617F allele burden was previously defined by a conventional enzymatic digestion method and in all cases AS-LAMP properly defined a tumor allele burden above or below 50% (data not shown).
Discussion
In this paper we described a new molecular assay for the identification of the JAK2V617F mutation. This assay is a non PCR DNA amplification method based on the LAMP principle and called AS-LAMP. LAMP is an innovative technique that rapidly amplifies DNA or RNA targets under isothermal conditions in which reagents react with high specificity, efficiency, and rapidity (27) . LAMP is performed using strand-displacement polymerase and avoiding the use of Taq DNA polymerase and thermal cycling. The potential diagnostic applications of this technology are remarkable and rapidly expanding particularly in the field of infectious disease (28) (29) (30) . The simplicity of its use is such that LAMP may be applied in low income, developing countries facing significant problems in healthcare (31) . The AS-LAMP we developed, allowed a rapid and robust identification of DNA samples harboring the JAK2V617F mutation. No false positive or negative results were registered when compared to those obtained by ASO-PCR or direct sequencing. This new assay proved also remarkably sensitive since the mutated JAK2V617F DNA could be detected down to 0.01% with a reproducible sensitivity of 0.1%. Finally, the assay allows an accurate definition, higher or lower than 50%, of the JAK2V617F allele burden. The method we describe is rapid, easy to perform and it requires neither a thermal cycler equipment nor gel separation, thus reducing the risk of contamination due to post amplification manipulations and the costs of the procedure. In fact, the proceeding reaction is visible to the naked eye and can be monitored by RealTime turbidimetry thanks to pyrophosphate salts generated as a by-product of the DNA amplification process (32) . When compared to other molecular methods currently employed to detect JAK2V617F mutation, AS-LAMP proved more sensitive than ASO-PCR, more accurate than enzymatic digestion of the PCR products and does not require the use of Real-Time PCR instrumentation. All these characteristics make this method feasible in routine diagnostic laboratories even in the absence of major technical infrastructures or highly qualified personnel.
The simplicity and rapidity of AS-LAMP (less than 1 hour versus at least 4 hours for ASO-PCR)
allows processing the clinical sample immediately after sampling without the support of a specialized molecular laboratory. When considering the widespread request of a molecular diagnostic profile for patients with a suspect chronic myeloproliferative disorder, this assay may represent a substantial improvement.
When compared to ASO-PCR, this method significantly increases our ability to detect a low tumor allele burden that is important in monitoring patients treated with the aim to eradicate the disease such as those undergoing allogeneic transplantation (33) .
The evaluation of the tumor allele burden is clinically relevant since different studies report that a high allele burden is associated to a faster transformation to MF and AML (12) (13) (14) (15) and to a higher risk of thrombotic events (34-36). In its present form AS-LAMP is able to detect 
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